Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Analysts at GlobalData think that faricimab and another Roche-developed product will be the main derivers of the market in the coming years. The companion product – Susvimo – is an implantable ...

In other recent news, Genentech, a part of Roche Group, announced the FDA's approval of Susvimo for the treatment of diabetic macular edema (DME). The approval follows positive results from the ...

For instance, in February 2024, Roche announced that the US Food and Drug Administration (FDA) approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand.

Finally, DeWilde explored future developments in anti-VEGF treatment, including biosimilars, implantable devices like Susvimo, and potential new delivery methods such as eye drops. He emphasized ...

Public Service Commissioner Sir Brian Roche fears the sheer number of entities, departments and agencies – some of which are small – creates inefficiencies and duplication.